{"sent_idx": "8", "frame_idx": "0", "ev": "After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32\u20130.91; P = 0.019).", "icos": [["1", "placebo", "risedronate", "hip fracture"]], "sample": "x"}
{"sent_idx": "16", "frame_idx": "1", "ev": "After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32\u20130.91; P = 0.019).", "icos": [["1", "placebo", "risedronate", "hip fracture"]], "sample": "x"}
{"sent_idx": "42", "frame_idx": "3", "ev": "Compared with placebo, risedronate 2.5 mg or 5.0 mg once daily reduced the risk of hip fracture by 46% (relative risk [RR] 0.54; 95% CI 0.32\u20130.91; P = 0.019) in women aged 70\u2013100 years with established osteoporosis (Table 3).3 This was a numerical larger risk reduction than that found in the overall ITT population from the HIP study (RR 0.7; 95% CI 0.6\u20130.9; P = 0.02) (Table 3).", "icos": [["1", "risedronate", "placebo", "risk of hip fracture"]], "sample": "x"}
{"sent_idx": "46", "frame_idx": "4", "ev": "The HIP study demonstrated that, compared with placebo, risedronate significantly reduced the risk of hip fracture in the overall ITT population by 30% (RR 0.7; 95% CI 0.6\u20130.9; P = 0.02).3 In women aged 70\u201379 years with low BMD, risedronate reduced the risk of hip fracture by 40% (RR 0.6; 95% CI 0.4\u20130.9; P = 0.009), and in those with low BMD and a prevalent vertebral fracture by 60% (RR 0.4; 95% CI 0.2\u20130.8; P = 0.003).", "icos": [["1", "risedronate", "placebo", "risk of hip fracture"]], "sample": "x"}
{"sent_idx": "49", "frame_idx": "6", "ev": "The present study demonstrates that risedronate is efficacious in older postmenopausal women with established osteoporosis, reducing the risk of hip fracture by 46% compared with placebo.", "icos": [["1", "placebo", "risedronate", "hip fracture"]], "sample": "x"}
{"sent_idx": "52", "frame_idx": "7", "ev": "Over 3-years, hip fracture incidence was reduced from 2.5% in the placebo group to 1.4% with annual infusions of zoledronic acid (RR 0.59; 95% CI 0.42\u20130.83; P = 0.002).4  It has also been documented that drug treatment aimed at improving the bone component of fracture risk is effective when patients have well-defined bone-related risk.", "icos": [["1", "placebo", "zoledronic acid", "hip fracture incidence"]], "sample": "x"}
{"sent_idx": "47", "frame_idx": "5", "ev": "In contrast, active treatment did not significantly reduce the incidence of hip fracture compared with placebo among women aged \u226580 years (RR 0.8; 95% CI 0.6\u20131.2; P = 0.35).", "icos": [["0.988524", "placebo", "fall prevention advice", "incidence of hip fracture"], ["0.9839864", "placebo", "vitamin D", "incidence of hip fracture"], ["0.9817981", "placebo", "1000 mg elemental calcium", "incidence of hip fracture"], ["0.9765862", "placebo", "placebo - controlled", "incidence of hip fracture"], ["0.9742244", "placebo", "drug treatment", "incidence of hip fracture"]], "sample": "c"}
{"sent_idx": "60", "frame_idx": "8", "ev": "The findings of this analysis show that risedronate is effective in reducing the risk of hip fracture in elderly women aged up to 100 years with established osteoporosis.", "icos": [["0.999622", "risedronate", "Risedronate", "risk of hip fracture"], ["0.999622", "risedronate", "risedronate", "risk of hip fracture"], ["0.999508", "risedronate", "Risedronate Therapy", "risk of hip fracture"], ["0.99924505", "risedronate", "bone - directed therapy", "risk of hip fracture"], ["0.9992054", "risedronate", "zoledronic acid", "risk of hip fracture"]], "sample": "c"}
